單永強(qiáng)博士，于中國(guó)醫(yī)科大學(xué)獲得臨床醫(yī)學(xué)學(xué)士和分子生物學(xué)碩士學(xué)位，于清華大學(xué)和北京協(xié)和醫(yī)學(xué)院獲得分子藥理學(xué)博士學(xué)位，后于中國(guó)醫(yī)學(xué)科學(xué)院進(jìn)行博士后研究工作。 單永強(qiáng)博士從事新藥研發(fā)工作18年，積累了豐富的經(jīng)驗(yàn)，在復(fù)雜疾病的疾病生物學(xué)和藥理學(xué)領(lǐng)域有深厚的造詣。在加入復(fù)宏漢霖之前，單博士曾先后服務(wù)于國(guó)家人類基因組北方研究中心、北京大學(xué)分子醫(yī)學(xué)研究所、諾華(中國(guó))生物醫(yī)學(xué)研究中心、華領(lǐng)醫(yī)藥、恒瑞醫(yī)藥，以及君圣泰生物等大型研究機(jī)構(gòu)及企業(yè)，擔(dān)任科學(xué)家、研究與早期開發(fā)部總監(jiān)、靶點(diǎn)研究部負(fù)責(zé)人、轉(zhuǎn)化科學(xué)副總裁/上海研發(fā)中心負(fù)責(zé)人等職務(wù)。 ? Dr. Yongqiang Shan got his B.Med. in Clinical Medicine and M.S. in Molecular Biology from China Medical University, and PhD. in Molecular Pharmacology from Tsinghua University & Peking Union Medical College. He then continued postdoctoral research in Chinese Academy of Medical Sciences. Dr. Shan has over 18 years of new drug research and development experience, with enormous knowledge in disease biology and pharmacology of complex diseases. Prior to joining Henlius, Dr. Shan has served as Scientist at CHGB, Institute of Molecular Medicine of Peking University and China Novartis Institute of Biomedical Research, as Director of Research and Early Development at Hua Medicine, as Head of Discovery Biology at Hengrui Pharmaceutical, and VP of Translational Science/Head of Shanghai R&D Center at HighTide Therapeutics. |